Inhibikase IKT (Parkinson's) MK $33Mio -> 5Mrd+ bis Ende 2023(?!) (Seite 2)
eröffnet am 24.01.22 11:02:17 von
neuester Beitrag 16.05.24 05:02:15 von
neuester Beitrag 16.05.24 05:02:15 von
Beiträge: 28
ID: 1.356.796
ID: 1.356.796
Aufrufe heute: 40
Gesamt: 2.597
Gesamt: 2.597
Aktive User: 0
ISIN: US45719W1062 · WKN: A2QAMK · Symbol: IQT
0,5500
EUR
-16,67 %
-0,1100 EUR
Letzter Kurs 30.06.23 Frankfurt
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5080 | +102,39 | |
| 17,650 | +96,11 | |
| 23,250 | +19,23 | |
| 23,900 | +13,49 | |
| 2,1250 | +13,03 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7500 | -14,29 | |
| 26,00 | -16,13 | |
| 8,0001 | -33,33 | |
| 25,00 | -37,50 | |
| 1,0000 | -47,37 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 72.281.538 von soulist am 26.08.22 15:44:49Der Booooom fehlt schon noch
Antwort auf Beitrag Nr.: 72.280.959 von Schumlim999 am 26.08.22 14:47:01
...und es hat BOOM gemacht
Jetzt gilt es erstmal die Dollarmarke beim Kurs zu halten eh wir ein oder zwei Nullen hinten anhängen
Zitat von Schumlim999: Inhibikase Therapeutics gibt die FDA-Zulassung für den Prüfantrag für ein neues Medikament für IkT-001Pro zur Behandlung von chronischer myeloischer Leukämie bekannt
...und es hat BOOM gemacht
Jetzt gilt es erstmal die Dollarmarke beim Kurs zu halten eh wir ein oder zwei Nullen hinten anhängen
Inhibikase Therapeutics gibt die FDA-Zulassung für den Prüfantrag für ein neues Medikament für IkT-001Pro zur Behandlung von chronischer myeloischer Leukämie bekannt
Teddy313
Bullish
40m $IKT
Years ago news like this would send the stock up a buck, different world now. This is big news for the many Parkinson patients and all the fellow longs in the stock. Let's just hope the drug works....
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Tue, August 23, 2022 at 2:00 PM
...
"Dosing of the first patient in our Phase 2a '201' trial represents a major milestone in the development of IkT-148009 for the treatment of Parkinson's disease and related disorders," commented Milton H. Werner, Ph.D., President and Chief Executive Officer. "Parkinson's disease remains one of the most prevalent neurodegenerative disorders and affects nearly one million people in the U.S. annually. Our research continues to validate the critical role that c-Abl, a mechanistically defined target, plays in the initiation and progression of Parkinson's disease, as well as the potential of IkT-148009 as a promising new approach to disease modification. Preclinical data in animal models of human PD suggested that functional recovery could be achieved in less than 8 weeks in animal."
https://finance.yahoo.com/news/inhibikase-therapeutics-annou…
Bullish
40m $IKT
Years ago news like this would send the stock up a buck, different world now. This is big news for the many Parkinson patients and all the fellow longs in the stock. Let's just hope the drug works....
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Tue, August 23, 2022 at 2:00 PM
...
"Dosing of the first patient in our Phase 2a '201' trial represents a major milestone in the development of IkT-148009 for the treatment of Parkinson's disease and related disorders," commented Milton H. Werner, Ph.D., President and Chief Executive Officer. "Parkinson's disease remains one of the most prevalent neurodegenerative disorders and affects nearly one million people in the U.S. annually. Our research continues to validate the critical role that c-Abl, a mechanistically defined target, plays in the initiation and progression of Parkinson's disease, as well as the potential of IkT-148009 as a promising new approach to disease modification. Preclinical data in animal models of human PD suggested that functional recovery could be achieved in less than 8 weeks in animal."
https://finance.yahoo.com/news/inhibikase-therapeutics-annou…
Antwort auf Beitrag Nr.: 72.196.668 von soulist am 15.08.22 13:46:53Earnings Call Transcript
Inhibikase Therapeutics, Inc. (IKT) CEO Milton Werner on Q2 2022 Results
https://seekingalpha.com/article/4534420-inhibikase-therapeu…
Inhibikase Therapeutics, Inc. (IKT) CEO Milton Werner on Q2 2022 Results
https://seekingalpha.com/article/4534420-inhibikase-therapeu…
Trading Spotlight
Inhibikase Therapeutics, Inc.
278 Follower:innen
15 Min. • vor 15 Minuten
Today at 8:00am ET, Inhibikase will host a conference call and webcast to provide a corporate update and review its second quarter financial results. Listen to the live webcast here: https://bit.ly/3JC8Teu
278 Follower:innen
15 Min. • vor 15 Minuten
Today at 8:00am ET, Inhibikase will host a conference call and webcast to provide a corporate update and review its second quarter financial results. Listen to the live webcast here: https://bit.ly/3JC8Teu
Zur Linksammlung hinzugefügt.
Hatte mir gewünscht, dass Joe ein Interview ohne seine Minions macht - check - leider akustisch ganz schlimm, aber mit englischen Untertiteln wirds besser
Hatte mir gewünscht, dass Joe ein Interview ohne seine Minions macht - check - leider akustisch ganz schlimm, aber mit englischen Untertiteln wirds besser
Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
JUNE 13, 2022 8:00AM EDT
"...Following a review of IkT-148009 safety, tolerability and PK data in the first two cohorts of the 101 trial in Parkinson's patients at 50 and 100 mg as well as the 201 trial protocol, the FDA agreed with the Company's view that proceeding with the 201 trial was appropriate without restrictions. Based on this feedback, Inhibikase will continue to advance the 201 trial and end enrollment of the 101 trial..."
https://www.inhibikase.com/news/press-releases/detail/56/inh…
soufre88
4m
$IKT Hmm Monkeypox patent. Inhibition of c-Abl for monkeypox. BIG!
https://stocktwits.com/soufre88/message/463365655
4m
$IKT Hmm Monkeypox patent. Inhibition of c-Abl for monkeypox. BIG!
https://stocktwits.com/soufre88/message/463365655
BOOM
Durchsuchen
